公开(公告)号：US20240343710A1

公开(公告)日：2024-10-17

申请号：US18583024

申请日：2024-02-21

申请人： 1cBio, Inc.

发明人： Jayakanth KANKANALA ,  Jeremy D. PETTIGREW ,  Son Minh PHAM

IPC分类号： C07D401/14 ,  A61K31/439 ,  A61K31/444 ,  A61K31/501 ,  A61K31/5383 ,  A61P31/00 ,  C07D407/14 ,  C07D487/08 ,  C07D487/16 ,  C07D498/16

CPC分类号： C07D401/14 ,  A61K31/439 ,  A61K31/444 ,  A61K31/501 ,  A61K31/5383 ,  A61P31/00 ,  C07D407/14 ,  C07D487/08 ,  C07D487/16 ,  C07D498/16

摘要： The present disclosure relates to compounds of Formula (I):




and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating PARP1 activity and may be used in the treatment of disorders in which PARP1 activity is implicated, such as cancer.

公开(公告)号：US20240342171A1

公开(公告)日：2024-10-17

申请号：US18294472

申请日：2022-08-16

申请人： Nanyang Technological University

发明人： Gerhard GRÜBER ,  Roderick Wayland BATES ,  Priya RAGUNATHAN

IPC分类号： A61K31/505 ,  A61K31/498 ,  A61K45/06 ,  A61P31/00

CPC分类号： A61K31/505 ,  A61K31/498 ,  A61K45/06 ,  A61P31/00

摘要： Disclosed herein is the use of a compound of formula I, or a salt or a solvate thereof, in the treatment of a bacterial infection caused by Mycobacterium abscessus, where the compound of formula (I) has the following formula: I where: R1, Ra, R2, R3, X, Y, Z and R4 are as defined herein. Also disclosed herein are combination treatments using the compound of formula I and pharmaceutical formulations comprising said compound.

公开(公告)号：US12115184B2

公开(公告)日：2024-10-15

申请号：US17343471

申请日：2021-06-09

申请人： AMORPHICAL LTD.

发明人： Yosef Ben ,  Yigal Dov Blum ,  Hagay Moshe ,  Ben Ashkenazi

IPC分类号： A61K33/10 ,  A61K9/00 ,  A61K9/10 ,  A61K9/14 ,  A61K47/24 ,  A61P31/00 ,  A61P35/00

CPC分类号： A61K33/10 ,  A61K9/0019 ,  A61K9/0056 ,  A61K9/0073 ,  A61K9/10 ,  A61K9/143 ,  A61K47/24 ,  A61P31/00 ,  A61P35/00

摘要： The present invention provides solid compositions of amorphous calcium carbonate (ACC) and a polyphosphate, bisphosphonate or pharmaceutical salts thereof as a stabilizer. Said stabilizers stabilizes the ACC and prevent crystallization to crystalline calcium carbonate (CCC) for a long period of time, even in an aqueous suspension. The invention further provides pharmaceutical composition comprising the solid ACC compositions as well their use in treating of certain diseases and conditions.

公开(公告)号：US12110320B2

公开(公告)日：2024-10-08

申请号：US17698645

申请日：2022-03-18

申请人： The University of North Carolina at Chapel Hill

发明人： Samuel Lai ,  M. Gregory Forest ,  Christine Henry ,  Timothy Wessler ,  Alexander Chen ,  Jennifer Schiller ,  Jay Newby

IPC分类号： A61K39/04 ,  A61P31/00 ,  C07K16/08 ,  C07K16/10 ,  C07K16/12 ,  C07K16/44 ,  G01N33/543 ,  G01N33/557 ,  G01N33/569 ,  G01N33/68 ,  A61K38/00

CPC分类号： C07K16/1235 ,  A61P31/00 ,  C07K16/087 ,  C07K16/1045 ,  C07K16/44 ,  G01N33/54346 ,  G01N33/557 ,  G01N33/56983 ,  G01N33/6854 ,  A61K38/00 ,  C07K2317/41 ,  G01N2333/16 ,  G01N2333/4725

摘要： The presently-disclosed subject matter relates to crosslinkers, compositions, and methods for trapping a target of interest on a substrate of interest. The methods may be used to inhibit and treat pathogen infection and provide contraception. The methods may be used to trap or separate particles and other substances. The subject matter further relates to methods of identifying and preparing optimal crosslinkers and methods for manipulating targets of interest.

公开(公告)号：US20240285723A1

公开(公告)日：2024-08-29

申请号：US18573517

申请日：2022-06-22

申请人： RAMOT AT TEL-AVIV UNIVERSITY LTD.

发明人： Yankel GABET ,  Josef MOGRABI

IPC分类号： A61K38/08 ,  A61K31/015 ,  A61K31/497 ,  A61K31/566 ,  A61K31/573 ,  A61P31/00 ,  A61P37/06

CPC分类号： A61K38/08 ,  A61K31/015 ,  A61K31/497 ,  A61K31/566 ,  A61K31/573 ,  A61P31/00 ,  A61P37/06

摘要： Pharmaceutical compositions are provided, comprising at least one selective CB2 receptor agonist and at least one steroid. The provided compositions are effective in treating inflammation and/or pathogen related inflammation and associated complications thereof. Also provided are methods for treating a subject infected with a pathogen as well as inflammation, using said compositions.

公开(公告)号：US20240269231A1

公开(公告)日：2024-08-15

申请号：US18616600

申请日：2024-03-26

申请人： Ohio University

发明人： John J. Kopchick ,  Vishwajeet Puri ,  Vishva Sharma ,  Reetobrata Basu

IPC分类号： A61K38/17 ,  A61P31/00 ,  A61P35/00

CPC分类号： A61K38/1761 ,  A61P31/00 ,  A61P35/00

摘要： FSP27 compositions and methods for treating cancers are described.

公开(公告)号：US20240261197A1

公开(公告)日：2024-08-08

申请号：US18443435

申请日：2024-02-16

申请人： SYMRISE AG

发明人： Imke MEYER ,  Ravikumar PILLAI

IPC分类号： A61K8/34 ,  A61K8/24 ,  A61K8/35 ,  A61K8/92 ,  A61P31/00

CPC分类号： A61K8/347 ,  A61K8/24 ,  A61K8/35 ,  A61K8/92 ,  A61P31/00

摘要： Suggested is an antimicrobial mixture comprising or consisting of



(a) at least one monocyclic sesquiterpene alcohol,
(b) at least one active selected from the group consisting of 4-hydroxyacetophenone, sorbitan caprylate, cocamidopropyl PG-dimonium chloride phosphate, tetrasodium glutamate diacetate, glyceryl caprylate and glyceryl caprate, and optionally
(c) at least one additional antimicrobial agent different from components (a) and (b).

公开(公告)号：US20240189237A1

公开(公告)日：2024-06-13

申请号：US18285645

申请日：2021-04-07

申请人： WATERSHED MEDICAL INC

发明人： Christopher R. KINSELLA, Jr. ,  Saniya ALI ,  Clay Justin NOLAN ,  Rush Lloyd BARTLETT, II

IPC分类号： A61K9/16 ,  A61K9/00 ,  A61K31/546 ,  A61K31/555 ,  A61P31/00

CPC分类号： A61K9/1676 ,  A61K9/0034 ,  A61K9/1617 ,  A61K9/1641 ,  A61K31/546 ,  A61K31/555 ,  A61P31/00

摘要： The invention provides a formulation and method for the treatment of urinary system disorders, wherein the formulation comprises a controlled release drug delivery system for intravesicular administration to a patient. Controlled release microparticles in the formulation are comprised of a pharmacologically active agent and a controlled release carrier, where the microparticles are buoyant in urine. Microparticle buoyancy in urine ensures that the formulation continues to release the active agent into a patient's bladder throughout the duration of an extended drug delivery time period. Methods of treating urinary system disorders by intravesicular administration of the microparticle formulation to a subject are also provided, and include methods of treating urinary system infections, bladder cancer, incontinence, and other urinary system disorders.

公开(公告)号：US20240182579A1

公开(公告)日：2024-06-06

申请号：US18493568

申请日：2023-10-24

申请人： Tayu Huaxia Biotech Medical Group Co., LTD.

发明人： Lieping CHEN ,  Liqun LUO

IPC分类号： C07K16/28 ,  A61K39/00 ,  A61P19/02 ,  A61P31/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/02 ,  C12N15/63 ,  C12N15/85

CPC分类号： C07K16/2827 ,  A61P19/02 ,  A61P31/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/02 ,  C07K16/2818 ,  C12N15/63 ,  C12N15/85 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C12N2015/8518

摘要： Provided are anti-PD-1 antibodies or fragments thereof. In various example, the antibodies or fragments thereof includes a heavy chain variable region comprising heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, and a light chain variable region comprising light chain complementarity determining regions LCDR1, LCDR2, and LCDR3. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer, infection or immune disorders are also provided.

公开(公告)号：US20240173512A1

公开(公告)日：2024-05-30

申请号：US18391989

申请日：2023-12-21

申请人： Beyond Air LTD

发明人： Yossef AV-GAY ,  David GREENBERG ,  Asher TAL

IPC分类号： A61M16/12 ,  A61K33/00 ,  A61K45/06 ,  A61P31/00 ,  A61B5/083 ,  A61B5/145

CPC分类号： A61M16/12 ,  A61K33/00 ,  A61K45/06 ,  A61P31/00 ,  A61B5/0833 ,  A61B5/14507 ,  A61M2202/0007 ,  A61M2202/0275

摘要： The invention provides a method of treating a subject having a medical condition associated with a pathogenic microorganism, the method comprising administering to said subject a potentiating effective amount of nitric oxide; and administering to said subject a therapeutically effective amount of an antimicrobial agent, wherein said antimicrobial agent is other than said nitric oxide.